Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Covalent Group Inc (CVGR) an undiscovered CRO -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (67)	11/11/1998 10:50:00 PM
From: vampire	Read Replies (1) \| Respond to of 107

what exactly does this virtual housecall system do?

To: JanyBlueEyes who wrote (67)	11/17/1998 12:11:00 PM
From: JanyBlueEyes	Read Replies (2) \| Respond to of 107

News - $600,000 Contract & Letter of Intent Covalent Group, Inc. Announces $600,000 Contract For Speech Recognition Services in a Clinical Study WAYNE, Pa., Nov. 17 /PRNewswire/ -- Covalent Group, Inc. (NASDAQ:CVGR) today announced receiving an award of a $600,000 contract to incorporate its propriety TeleTrial System, employing interactive speech recognition technology, with a previously announced $13.6 million clinical development study. The award of this additional contract brings the total value of the project to $14.2 million. "TeleTrial is an extension of our Virtual HouseCall speech recognition platform and will provide important value added services to clinical studies that we conduct," commented Bruce LaMont, President and Chief Executive Officer. "Additionally, TeleTrial enhances our Company's ability to conduct larger and longer clinical studies. More specifically, through TeleTrial we can offer our clients more efficient and cost effective access to study data by managing five important elements of a clinical study: shipment of medications; patient enrollment and randomization; retention of patients; clinical supplies management; and patient questionnaires." Mr. LaMont continued, "We have also obtained a letter of intent for another application of TeleTrial for use in a prospective client's clinical study, and we continue to pursue additional opportunities for application of this proprietary technology." Covalent provides drug development and health management solutions to pharmaceutical and device manufacturers, as well as managed care organizations. To aid its pharmaceutical and managed care customers, Covalent has developed a disease assessment system, Virtual HouseCall, and a clinical trial management system, TeleTrial, using interactive speech recognition technology. This press release contains forward-looking statements......